-
1
-
-
0037541057
-
Recent advances in the management of leukaemia
-
Will A. Recent advances in the management of leukaemia. Curr Paediatr 13 (2003) 201-206
-
(2003)
Curr Paediatr
, vol.13
, pp. 201-206
-
-
Will, A.1
-
2
-
-
0036042525
-
Translation of cure for acute lymphoblastic leukaemia to all children
-
Eden O.B. Translation of cure for acute lymphoblastic leukaemia to all children. Br J Haematol 118 (2002) 945-951
-
(2002)
Br J Haematol
, vol.118
, pp. 945-951
-
-
Eden, O.B.1
-
3
-
-
84857938873
-
Clinical features and therapy of lymphoblastic leukaemia
-
Arceci R.J., Hann I.M., and Smith O.P. (Eds), Blackwell, Oxford
-
Smith O.P., and Hann I.M. Clinical features and therapy of lymphoblastic leukaemia. In: Arceci R.J., Hann I.M., and Smith O.P. (Eds). Pediatric hematology. 3rd Edn. (2006), Blackwell, Oxford 450-581
-
(2006)
Pediatric hematology. 3rd Edn.
, pp. 450-581
-
-
Smith, O.P.1
Hann, I.M.2
-
4
-
-
0035128616
-
Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia
-
Goulden N., Oakhill A., and Steward C. Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 112 (2001) 275-281
-
(2001)
Br J Haematol
, vol.112
, pp. 275-281
-
-
Goulden, N.1
Oakhill, A.2
Steward, C.3
-
5
-
-
0032576355
-
Prognostic value of MRD in ALL in children
-
van Dongen J.J., Seriu T., Payer-Grumayer E.R., et al. Prognostic value of MRD in ALL in children. Lancet 352 (1998) 1731-1738
-
(1998)
Lancet
, vol.352
, pp. 1731-1738
-
-
van Dongen, J.J.1
Seriu, T.2
Payer-Grumayer, E.R.3
-
6
-
-
0034525991
-
Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997
-
Eden O.B., Harrison G., Richards S., et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Leukaemia 12 (2000) 2307-2320
-
(2000)
Leukaemia
, vol.12
, pp. 2307-2320
-
-
Eden, O.B.1
Harrison, G.2
Richards, S.3
-
7
-
-
34447519040
-
'Interfant 06'-novel protocol increases survival in infants with acute lymphoblastic leukaemia
-
Pieters R., Schrappe M., De Cronig P., et al. 'Interfant 06'-novel protocol increases survival in infants with acute lymphoblastic leukaemia. Lancet 370 (2007) 240-250
-
(2007)
Lancet
, vol.370
, pp. 240-250
-
-
Pieters, R.1
Schrappe, M.2
De Cronig, P.3
-
8
-
-
0032572912
-
Acute lymphoblastic leukaemia
-
Pui C.-H., and Evans W.E. Acute lymphoblastic leukaemia. N Engl J Med 339 (1998) 606-615
-
(1998)
N Engl J Med
, vol.339
, pp. 606-615
-
-
Pui, C.-H.1
Evans, W.E.2
-
9
-
-
0034611661
-
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia
-
Arico M., Valsecchi M.C., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia. N Engl J Med 342 (2000) 998-1006
-
(2000)
N Engl J Med
, vol.342
, pp. 998-1006
-
-
Arico, M.1
Valsecchi, M.C.2
Camitta, B.3
-
10
-
-
0032532289
-
Philadelphia chromosome-positive childhood acute lymphoblastic leukaemia: good initial steroid response allows early prediction of a favourable treatment outcome
-
Scrappe M., Arico M., Harbott J., et al. Philadelphia chromosome-positive childhood acute lymphoblastic leukaemia: good initial steroid response allows early prediction of a favourable treatment outcome. Blood 92 (1998) 2730-2741
-
(1998)
Blood
, vol.92
, pp. 2730-2741
-
-
Scrappe, M.1
Arico, M.2
Harbott, J.3
-
11
-
-
0033585485
-
A BCR/ABL kinase antagonist for CML: a promising path for progress emerges
-
Sausville E.A. A BCR/ABL kinase antagonist for CML: a promising path for progress emerges. J Natl Cancer Inst 91 (1999) 102-103
-
(1999)
J Natl Cancer Inst
, vol.91
, pp. 102-103
-
-
Sausville, E.A.1
-
12
-
-
0037105560
-
Results of a phase II study to determine the safety and anti-leukaemic effects of imatinib in adults with Philadelphia positive leukaemia
-
Ottmann O.G., Druker B., Sawyers C., et al. Results of a phase II study to determine the safety and anti-leukaemic effects of imatinib in adults with Philadelphia positive leukaemia. Blood 100 (2002) 1965-1971
-
(2002)
Blood
, vol.100
, pp. 1965-1971
-
-
Ottmann, O.G.1
Druker, B.2
Sawyers, C.3
-
13
-
-
0027941369
-
Intensive post remission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B
-
Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive post remission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 (1994) 896-903
-
(1994)
N Engl J Med
, vol.331
, pp. 896-903
-
-
Mayer, R.J.1
Davis, R.B.2
Schiffer, C.A.3
-
14
-
-
0035397980
-
Efficacy and safety of Gemtuzumab in patients with CD33-positive acute myeloid leukemia in first relapse
-
Sievers E.L., Larson Rarjian A., Stadtmauer E.A., et al. Efficacy and safety of Gemtuzumab in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19 (2001) 3244-3254
-
(2001)
J Clin Oncol
, vol.19
, pp. 3244-3254
-
-
Sievers, E.L.1
Larson Rarjian, A.2
Stadtmauer, E.A.3
-
15
-
-
34249775270
-
The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC15 trial
-
(abstract 13)
-
Burnett A.K., Kell W.J., Goldstone A.H., et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC15 trial. Blood 108 (2007) 8a (abstract 13)
-
(2007)
Blood
, vol.108
-
-
Burnett, A.K.1
Kell, W.J.2
Goldstone, A.H.3
-
16
-
-
0037097716
-
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukaemia: association with FAB subtypes and identification of subgroups with a poor prognosis
-
Theide C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukaemia: association with FAB subtypes and identification of subgroups with a poor prognosis. Blood 99 (2002) 4326-4335
-
(2002)
Blood
, vol.99
, pp. 4326-4335
-
-
Theide, C.1
Steudel, C.2
Mohr, B.3
-
17
-
-
33751180608
-
A phase II trial of the FLT-3 inhibitor CEP-701 as first line treatment for older patients with AML not considered fit for intensive chemotherapy
-
Knapper S., Burnett A.K., Kell J., et al. A phase II trial of the FLT-3 inhibitor CEP-701 as first line treatment for older patients with AML not considered fit for intensive chemotherapy. Blood 104 (2004) 246a-247a
-
(2004)
Blood
, vol.104
-
-
Knapper, S.1
Burnett, A.K.2
Kell, J.3
-
18
-
-
18544375333
-
MLL gene translocations specify a distinct gene expression profile that distinguishes a unique leukaemia
-
Armstrong S.A., Staunton J.E., Silverman L.B., et al. MLL gene translocations specify a distinct gene expression profile that distinguishes a unique leukaemia. Nat Genet 30 (2002) 41-47
-
(2002)
Nat Genet
, vol.30
, pp. 41-47
-
-
Armstrong, S.A.1
Staunton, J.E.2
Silverman, L.B.3
-
19
-
-
0033230342
-
A modified AIDA protocol with anthracycline-based consolidation results in high anti-leukaemia efficacy and reduced toxicity in newly diagnosed/RAR positive APML
-
Sanz M., Martin E., Rayon L., et al. A modified AIDA protocol with anthracycline-based consolidation results in high anti-leukaemia efficacy and reduced toxicity in newly diagnosed/RAR positive APML. Blood 94 (1999) 3015-3021
-
(1999)
Blood
, vol.94
, pp. 3015-3021
-
-
Sanz, M.1
Martin, E.2
Rayon, L.3
-
20
-
-
0035884639
-
United States multicentre study of arsenic trioxide in relapsed acute promyelocytic leukaemia
-
Soignet S.L., Frankel S.R., Douer D., et al. United States multicentre study of arsenic trioxide in relapsed acute promyelocytic leukaemia. J Clin Oncol 19 (2001) 3852-3860
-
(2001)
J Clin Oncol
, vol.19
, pp. 3852-3860
-
-
Soignet, S.L.1
Frankel, S.R.2
Douer, D.3
-
21
-
-
0142058034
-
Down's syndrome and acute myeloid leukaemia: the paradox of increased risk and heightened sensitivity to chemotherapy-an editorial
-
Ravindranath Y. Down's syndrome and acute myeloid leukaemia: the paradox of increased risk and heightened sensitivity to chemotherapy-an editorial. J Clin Oncol 212 (2003) 3385-3387
-
(2003)
J Clin Oncol
, vol.212
, pp. 3385-3387
-
-
Ravindranath, Y.1
-
22
-
-
76449091767
-
Relapsed acute myeloid leukaemia in children and adolescents: interim report of the international randomised phase III study Relapsed AML 2001/01
-
abstract 2013
-
Kaspers G.J., Zimmermann M., Fleischhack G., et al. Relapsed acute myeloid leukaemia in children and adolescents: interim report of the international randomised phase III study Relapsed AML 2001/01. Blood 108 (2007) 570a abstract 2013
-
(2007)
Blood
, vol.108
-
-
Kaspers, G.J.1
Zimmermann, M.2
Fleischhack, G.3
-
23
-
-
0041737629
-
Stem cell transplantation for chronic myeloid leukaemia in children
-
Cwynarski K., Roberts I.A.G., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukaemia in children. Blood 102 (2003) 1224-1231
-
(2003)
Blood
, vol.102
, pp. 1224-1231
-
-
Cwynarski, K.1
Roberts, I.A.G.2
Iacobelli, S.3
|